Encysive Rules Out FDA Dispute Resolution Path For Thelin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects to have 35 sales reps for European, Canadian launch of Thelin by early next year, CEO says.
You may also be interested in...
Gilead’s Letairis Label Updated For Fluid Retention
Language similar to wording on competitor Tracleer.
United Therapeutics Reports ‘Solid’ Fourth Quarter As Inhaled Remodulin Gains Fans
Look for NDA filing for Viveta in June, approval in first half of 2009, analyst tells “The Pink Sheet” DAILY.
Gilead’s Letairis Label Updated For Fluid Retention
Language similar to wording on competitor Tracleer.